Granada Overdosage

Overdose data are limited. A specific toxic dose has not been established.
Similar to other atypical antipsychotic agents in that it has a propensity to produce extrapyramidal effects.
Lurasidone does have alpha-1-adrenergic antagonist activity which may produce hypotension and other hemodynamic effects.
There are limited experience on mild to moderate poisoning. Drowsiness/lethargy, vomiting, tachycardia, hypertension, hypotension, conduction disturbance, dystonia, and ataxia have been reported.
There is no information on severe toxicity with lurasidone. Severe overdose might cause hypotension and altered mental status.
Management of overdose: There is no specific antidote to lurasidone, therefore, appropriate supportive measures should be instituted, and close medical supervision and monitoring should continue until the patient recovers.
Cardiovascular monitoring should commence immediately, including continuous electrocardiographic monitoring for possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QT-prolonging effects when administered in patients with an acute overdose of lurasidone. Similarly, the alpha-blocking properties of bretylium might be additive to those of lurasidone, resulting in problematic hypotension. Hypotension and circulatory collapse should be treated with appropriate measures. Epinephrine and dopamine should not be used, or other sympathomimetics with beta-agonist activity, since beta stimulation may worsen hypotension in the setting of lurasidone-induced alpha blockade. In case of severe extrapyramidal symptoms, anticholinergic medication should be administered.
Gastric lavage (after intubation if patient is unconscious) and administration of activated charcoal together with a laxative should be considered. The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.